SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12B-25
Commission File Number: 0-11274
NOTIFICATION OF LATE FILING
(Check One): /_/ Form 10-K /_/ Form 11-K /_/ Form 20-F /x/ Form 10-Q
/_/ Form N-SAR
For Period Ended: MARCH 31, 1999
/_/ Transition Report on Form 10-K /_/ Transition Report on From 10-Q
/_/ Transition Report on Form 20-F /_/ Transition Report on Form N-SAR
/_/ Transition Report on Form 11-K
For the Transition Period Ended: __________________________________
READ ATTACHED INSTRUCTION SHEET BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates: _______________________
_______________________________________________________________________________
PART I
REGISTRANT INFORMATION
Full name of registrant PHARMACEUTICAL FORMULATIONS INC.
Former name if applicable ______________________________________________________
460 PLAINFIELD AVENUE
- --------------------------------------------------------------------------------
Address of principal executive office (STREET AND NUMBER)
EDISON, NJ 08818-1904
- --------------------------------------------------------------------------------
City, state and zip code
PART II
RULE 12B-25 (B) AND (C)
If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)
<PAGE>
| (a) The reasons described in reasonable detail in Part III of this form
| could not be eliminated without unreasonable effort or expense;
|
/_/ | (b) The subject annual report, semi-annual report, transition report on
| Form 10- K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed
| on or before the 15th calendar day following the prescribed due date; or
| the subject quarterly report or transition report on Form 10-Q, or
| portion thereof will be filed on or before the fifth calendar day
| following the prescribed due date; and
|
| (c) The accountant's statement or other exhibit required by Rule
| 12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K,
20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed
within the prescribed time period. (Attach extra sheets if needed.)
PHARMACEUTICAL FORMULATIONS, INC. (THE "COMPANY") COULD NOT COMPLETE
ITS FILING ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 1999 (THE MARCH 10-Q")
DUE TO A DELAY IN OBTAINING AND COMPILING INFORMATION REQUIRED TO BE INCLUDED IN
THE MARCH 10-Q, WHICH DELAY COULD NOT BE ELIMINATED BY THE COMPANY WITHOUT
UNREASONABLE EFFORT AND EXPENSE. THE DELAY IS CAUSED BY A PENDING REVIEW TO
RESTATE THE UNAUDITED EARNINGS OF THE TWO PREVIOUSLY REPORTED QUARTERS. THE
COMPANY IS NOT ABLE TO STATE AT THIS TIME WHEN SUCH INFORMATION WILL BE
AVAILABLE BUT DOES NOT BELIEVE THAT IT WILL BE ABLE TO FILE SUCH INFORMATION ON
OR BEFORE THE FIFTH CALENDAR DAY FOLLOWING THE PRESCRIBED DUE DATE.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
CLIFFORD STRAUB (732) 985-7100
- -------------------------------------------------------------------------------
(Name) (Area Code)(Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify reports(s).
/x/ Yes /_/ No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?
/_/ Yes /_/ No
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
THE COMPANY DOES NOT KNOW AT THIS TIME WHETHER THERE WILL BE ANY SIGNIFICANT
CHANGES IN THE RESULTS OF OPERATIONS.
PHARMACEUTICAL FORMULATIONS, INC.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date MAY 17, 1999 By: /S/ CLIFFORD STRAUB
------------ ------------------------------------
Clifford Straub
Senior Vice President-Chief Administrative
Officer and Chief Financial Officer
INSTRUCTION. The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and
title of the person signing the form shall be typed or printed beneath
the signature. If the statement is signed on behalf of the registrant by
an authorized representative (other than an executive officer), evidence
of the representative's authority to sign on behalf of the registrant
shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal
criminal violations (SEE 18 U.S.C.1001).
GENERAL INSTRUCTIONS
(1) This form is required by Rule 12b-25 of the General Rules and
Regulations under the Securities Exchange Act of 1934.
(2) One signed original and four conformed copies of this form and
amendments thereto must be completed and filed with the Securities and Exchange
Commission, Washington, DC 20549, in accordance with Rule 0-3 of the General
Rules and Regulations under the Act. The information contained in or filed with
the form will be made a matter of the public record in the Commission files.
(3) A manually signed copy of the form and amendments thereto shall be
filed with each national securities exchange on which any class of securities of
the registrant is registered.
(4) Amendments to the notifications must also be filed on Form 12b-25
but need not restate information that has been correctly furnished. The form
shall be clearly identified as an amended notification.
(5) ELECTRONIC FILERS. This form shall not be used by electronic
filers unable to timely file a report solely due to electronic difficulties.
Filers unable to submit a report within the time period prescribed due to
difficulties in electronic filing should comply with either Rule 201 or Rule 202
of Registration S-T or apply for an adjustment in filing date pursuant to Rule
13(b) of Regulation S-T.
